Akcea Therapeutics Inc (NASDAQ:AKCA) had its Hold rating reiterated by Stifel Nicolaus with a $33.00 price target

Analyst Ratings For Akcea Therapeutics Inc (NASDAQ:AKCA)

Story continues below

Today, Stifel Nicolaus reiterated its Hold rating on Akcea Therapeutics Inc (NASDAQ:AKCA) with a price target of $33.00.

There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Akcea Therapeutics Inc (NASDAQ:AKCA) is Buy with a consensus target price of $30.3333 per share, a potential 11.28% downside.

Some recent analyst ratings include

  • 8/7/2018-Stifel Nicolaus Reiterated Rating of Hold.
  • 5/11/2018-Wells Fargo & Co Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 2/27/2018-Cowen was Downgraded by analysts at Cowen from a “Outperform ” rating to a ” Market Perform” rating. They now have a N/A price target on the stock.

Recent Insider Trading Activity For Akcea Therapeutics Inc (NASDAQ:AKCA)
Akcea Therapeutics Inc (NASDAQ:AKCA) has insider ownership of 3.88% and institutional ownership of 23.96%.

  • On 4/17/2018 Ionis Pharmaceuticals Inc, Major Shareholder, bought 10,666,666 with an average share price of $18.75 per share and the total transaction amounting to $199,999,987.50.
  • On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.

About Akcea Therapeutics Inc (NASDAQ:AKCA)
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.

Recent Trading Activity for Akcea Therapeutics Inc (NASDAQ:AKCA)
Shares of Akcea Therapeutics Inc closed the previous trading session at 34,19 +0,32 0,94 % with 33.91 shares trading hands.

An ad to help with our costs